Lewis L Hsu

List of Publications by Year
in descending order

124	7,290	93792	64407
papers	citations	39 h-index	83 g-index

128	128	128	5726
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety of maximal cardiopulmonary exercise testing in individuals with sickle cell disease: a systematic review. British Journal of Sports Medicine, 2022, 56, 764-769.	3.1	2
2	COVID-19 and Sickle Cell Diseaseâ€“Related Deaths Reported in the United States. Public Health Reports, 2022, 137, 234-238.	1.3	8
3	Perspectives of individuals with sickle cell disease on barriers to care. PLoS ONE, 2022, 17, e0265342.	1.1	13
4	Motivators and Barriers to Physical Activity among Youth with Sickle Cell Disease: Brief Review. Children, 2022, 9, 572.	0.6	2
5	Trends in School Attendance for Lowâ€Income Children with Chronic Health Conditions: Results from a Randomized Controlled Trial. Journal of School Health, 2021, 91, 187-194.	0.8	2
6	Authorsâ€™ response. Journal of the American Dental Association, 2021, 152, 257.	0.7	0
7	Topical Vapocoolant-Associated Vaso-occlusive Event in a 10-year-old with Sickle Cell Disease. Pain Management Nursing, 2021, 22, 631-633.	0.4	0
8	Opening Pandoraâ€™s Box. Medical Care, 2021, 59, S336-S343.	1.1	6
9	Implementation of Complex Interventions. Medical Care, 2021, 59, S344-S354.	1.1	12
10	Improving VTE prophylaxis adherence among hospitalized adolescents using Human-Centered Design. Journal of Patient Safety and Risk Management, 2021, 26, 172-178.	0.4	1
11	Patientâ€reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. American Journal of Hematology, 2021, 96, 1396-1406.	2.0	15
12	coreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials. BMC Medical Research Methodology, 2021, 21, 219.	1.4	4
13	Nitrous Oxide for Dental Procedures in Pediatric Patients with Sickle Cell Disease: A Pilot Study.. Pediatric Dentistry (discontinued), 2021, 43, 481-483.	0.4	0
14	Letter to the Editor: A Quality Improvement Initiative for Pediatric Resident Education in Venous Thromboembolism Risk Assessment in Pediatric Patients. American Journal of Medical Quality, 2020, 35, 359-360.	0.2	2
15	Paediatric to adult transition care for patients with sickle cell disease: a global perspective. Lancet Haematology,the, 2020, 7, e329-e341.	2.2	22
16	Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia. Blood Advances, 2020, 4, 3311-3314.	2.5	1
17	A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. Annals of Emergency Medicine, 2020, 76, S64-S72.	0.3	22
18	Design of the patient navigator to Reduce Readmissions (PArTNER) study: A pragmatic clinical effectiveness trial. Contemporary Clinical Trials Communications, 2019, 15, 100420.	0.5	9

#	Article	IF	Citations
19	â€œMaximum tolerated doseâ€•vs â€œfixed lowâ€•doseâ€•hydroxyurea for treatment of adults with sickle cell anemia. American Journal of Hematology, 2019, 94, E112-E115.	2.0	7
20	Sickle Cell Diseaseâ€”Genetics, Pathophysiology, Clinical Presentation and Treatment. International Journal of Neonatal Screening, 2019, 5, 20.	1.2	80
21	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vasoâ€•occlusive pain. American Journal of Hematology, 2019, 94, 689-696.	2.0	17
22	Parent and Guardian Knowledge of Hematopoietic Cell Transplantation as a Treatment Option for Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2019, 41, 187-193.	0.3	6
23	An Electronic Teaching Module for Improving Knowledge of Self-Management of Vaso-Occlusive Pain Crises in Patients With Sickle Cell Disease: Pilot Questionnaire Study. JMIR MHealth and UHealth, 2019, 7, e13501.	1.8	2
24	Commentary on â€œHow Postbaccalaureate Career Changer and Traditional Medical Students Differ Academicallyâ€• Southern Medical Journal, 2019, 112, 617-618.	0.3	1
25	Program expansion of a day hospital dedicated to manage sickle cell pain. American Journal of Hematology, 2018, 93, E20-E21.	2.0	7
26	Utilising the â€˜Getting to OutcomesÂ®â€™ Framework in Community Engagement for Development and Implementation of Sickle Cell Disease Newborn Screening in Kaduna State, Nigeria. International Journal of Neonatal Screening, 2018, 4, 33.	1.2	5
27	White Paper: Pathways to Progress in Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa. Journal of Tropical Diseases, 2018, 06, 260.	0.1	19
28	The sickle cell disease implementation consortium: Translating evidenceâ€•based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395.	2.0	52
29	A doseâ€•ranging study of ticagrelor in children aged 3â€•17 years with sickle cell disease: A 2â€•part phase 2 study. American Journal of Hematology, 2018, 93, 1493-1500.	2.0	18
30	Fixed lowâ€•dose hydroxyurea for the treatment of adults with sickle cell anemia in<scp>N</scp>igeria. American Journal of Hematology, 2018, 93, E193.	2.0	11
31	A Phase 3 Trial of<scp>l</scp>-Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	13.9	378
32	Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings. F1000Research, 2018, 7, 1407.	0.8	4
33	Summer Camps for Children with Sickle Cell Disease. Ochsner Journal, 2018, 18, 358-363.	0.5	4
34	Timely Care for Sickle Cell. Joint Commission Journal on Quality and Patient Safety, 2017, 43, 113-115.	0.4	2
35	Self-Reported Physical Activity and Exercise Patterns in Children With Sickle Cell Disease. Pediatric Exercise Science, 2017, 29, 388-395.	0.5	13
36	Associations of Î±-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. Blood Advances, 2017, 1, 693-698.	2.5	12

#	Article	IF	Citations
37	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Medicine, 2017, 14, e1002382.	3.9	107
38	Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. Blood, 2017, 130, 981-981.	0.6	3
39	Evidence-Based Interventions Are Necessary but Not Sufficient for Achieving Outcomes in Each Setting in a Complex World. American Journal of Evaluation, 2016, 37, 544-561.	0.6	35
40	Community Health Workers as Support for Sickle Cell Care. American Journal of Preventive Medicine, 2016, 51, S87-S98.	1.6	57
41	Clinical Manifestations of Sickle Cell Anemia: Infants and Children. , 2016, , 213-229.		2
42	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve theÂQuality of Life of Adults with Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 441-448.	2.0	111
43	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	0.6	178
44	Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation. Journal of Sexual Medicine, 2015, 12, 1878-1885.	0.3	19
45	Platelets decline during <scp>V</scp>asoâ€occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. American Journal of Hematology, 2015, 90, E228-9.	2.0	12
46	Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease. Pharmacotherapy, 2015, 35, 696-700.	1.2	7
47	Assessment of Bone Marrow Function in Sickle Cell Anaemia Patients Using Corrected Reticulocyte Counts. Blood, 2015, 126, 4581-4581.	0.6	1
48	Impact of a Dedicated Sickle Cell Acute Care Observation Unit on Rate of Hospital Admission for Acute Pain Crisis. Blood, 2015, 126, 4584-4584.	0.6	0
49	A Survey of Resident Physicians' and Nurses' Knowledge of Severity Assessment of Acute Chest Syndrome and Role of Incentive Spirometry in Management. Blood, 2015, 126, 2064-2064.	0.6	0
50	Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 238-240.	2.5	1
51	Intravenous magnesium for pediatric sickle cell vasoâ€occlusive crisis: Methodological issues of a randomized controlled trial. Pediatric Blood and Cancer, 2014, 61, 1049-1054.	0.8	22
52	Pulmonary Hypertension of Sickle Cell Disease Beyond Classification Constraints. Journal of the American College of Cardiology, 2014, 63, 2881-2882.	1.2	2
53	Comparison of Patients from Nigeria and the USA Highlights Modifiable Risk Factors for Sickle Cell Anemia Complications. Hemoglobin, 2014, 38, 236-243.	0.4	24
54	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197

#	Article	IF	Citations
55	Neurodevelopmental Deficits Among Infants and Toddlers with Sickle Cell Disease. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 399-405.	0.6	25
56	IMPROVE trial: A randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clinical Trials, 2013, 10, 319-331.	0.7	46
57	An educational symposium for patients with sickle cell disease and their families: Results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2013, 60, 1946-1951.	0.8	17
58	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 â€“ A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood, 2013, 122, 2206-2206.	0.6	2
59	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	0.6	7
60	Sildenafil Citrate-Restored eNOS and PDE5 Regulation in Sickle Cell Mouse Penis Prevents Priapism Via Control of Oxidative/Nitrosative Stress. PLoS ONE, 2013, 8, e68028.	1.1	53
61	A Comparison Of Sickle Cell Anemia Between Patients From Nigeria and The United States. Blood, 2013, 122, 997-997.	0.6	0
62	Hydroxyurea makes inflammation â€œjust rightâ€?. Blood, 2012, 119, 1796-1798.	0.6	1
63	Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials, 2012, 33, 291-297.	0.8	58
64	Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vasoâ€•occlusive episodes. American Journal of Hematology, 2012, 87, E71-4.	2.0	4
65	Oxygen Regulates Tissue Nitrite Metabolism. Antioxidants and Redox Signaling, 2012, 17, 951-961.	2.5	39
66	Refining the value of secretory phospholipase <scp>A</scp>₂ as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (<scp>PROACTIVE</scp>). British Journal of Haematology, 2012, 157, 627-636.	1.2	42
67	Pain Medication: Time to First Dose in Sickle Cell Acute Care in Two Settings of a Large Urban Hospital. Blood, 2012, 120, 4693-4693.	0.6	0
68	Early Detection of Renal Dysfunction in Pediatric Sickle Cell Patients. Blood, 2012, 120, 1017-1017.	0.6	0
69	Comparing Abstract Numerical and Visual Depictions of Risk in Survey of Parental Assessment of Risk in Sickle Cell Hydroxyurea Treatment. Journal of Pediatric Hematology/Oncology, 2011, 33, 4-9.	0.3	4
70	Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology, 2011, 155, 263-267.	1.2	34
71	Post-Translational Inactivation of Endothelial Nitric Oxide Synthase in the Transgenic Sickle Cell Mouse Penis. Journal of Sexual Medicine, 2011, 8, 419-426.	0.3	21
72	Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: A phase III analgesic trial for hospitalized sickle cell patients with painful episodes. American Journal of Hematology, 2011, 86, E70-E73.	2.0	25

#	Article	IF	Citations
73	Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nature Communications, 2011, 2, 520.	5.8	83
74	Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis. JAMA - Journal of the American Medical Association, 2011, 305, 893.	3.8	196
75	Nitrite Oxidase Activities of Cytochrome P450 and Mitochondria. Blood, 2011, 118, 5310-5310.	0.6	0
76	Neurdevelopmental Deficits Among 80 Infants and Toddlers with Sickle Cell Disease. Blood, 2011, 118, 174-174.	0.6	0
77	Semi-automated method to measure pneumonia severity in mice through computed tomography (CT) scan analysis. Proceedings of SPIE, 2010, , .	0.8	0
78	SB203580, a p38 Inhibitor, Improved Cardiac Function but Worsened Lung Injury and Survival During Escherichia coli Pneumonia in Mice. Journal of Trauma, 2010, 68, 1317-1327.	2.3	14
79	Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2010, 16, 263-272.	2.0	165
80	Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes. Blood, 2010, 116, 2667-2667.	0.6	1
81	Peripheral Arterial Tonometry in Assessing Endothelial Dysfunction in Pediatric Sickle Cell Disease. IFMBE Proceedings, 2010, , 544-547.	0.2	0
82	Disparities In Pulmonary Complications of Sickle Cell Disease. Blood, 2010, 116, 2645-2645.	0.6	0
83	PERIPHERAL ARTERIAL TONOMETRY IN ASSESSING ENDOTHELIAL DYSFUNCTION IN PEDIATRIC SICKLE CELL DISEASE. Pediatric Hematology and Oncology, 2009, 26, 589-596.	0.3	15
84	Establishment of a Transgenic Sickle-Cell Mouse Model to Study the Pathophysiology of Priapism. Journal of Sexual Medicine, 2009, 6, 2494-2504.	0.3	64
85	Apoliprotein A-I Mimetic Peptide and Sickle Vasculopathy: Mouse Model Study of Acute Administration.. Blood, 2009, 114, 1521-1521.	0.6	0
86	Liver Hypoxia and Tissue Injury Are Specific to Sickle Cell Mice in An Experimental Model of Sickle Cell Vaso-Occlusion.. Blood, 2009, 114, 2569-2569.	0.6	0
87	Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radical Biology and Medicine, 2008, 44, 1506-1528.	1.3	208
88	The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H4-H7.	1.5	24
89	Ethyl pyruvate decreased early nuclear factor-ÎºB levels but worsened survival in lipopolysaccharide-challenged mice*. Critical Care Medicine, 2008, 36, 1059-1067.	0.4	22
90	C-Reactive Protein and Interleukin-6 Are Decreased in Transgenic Sickle Cell Mice Fed a High Protein Diet. Journal of Nutrition, 2008, 138, 1148-1152.	1.3	29

#	Article	IF	Citations
91	Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood, 2007, 109, 3088-3098.	0.6	241
92	Physician-diagnosed asthma and acute chest syndrome: Associations with NOS Polymorphisms. Pediatric Pulmonology, 2007, 42, 332-338.	1.0	39
93	Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. British Journal of Haematology, 2007, 136, 673-676.	1.2	45
94	Parthenolide has limited effects on nuclear factor-Îºî²2 increases and worsens survival in lipopolysaccharide-challenged C57BL/6J mice. Cytokine, 2006, 33, 299-308.	1.4	22
95	Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. Journal of Pediatrics, 2006, 149, 710-712.	0.9	135
96	STARBRIGHT World: A Pilot Study of a Home-Based Sickle Cell Psychoeducational Intervention. Children's Health Care, 2006, 35, 321-338.	0.5	13
97	Pathology of â€œBerkeleyâ€•sickle-cell mice includes gallstones and priapism. Blood, 2006, 107, 3414-3415.	0.6	18
98	Erythropoiesis and Myocardial Energy Requirements Contribute to the Hypermetabolism of Childhood Sickle Cell Anemia. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 680-687.	0.9	43
99	Proinflammatory Cytokines and the Hypermetabolism of Children with Sickle Cell Disease. Experimental Biology and Medicine, 2005, 230, 68-74.	1.1	87
100	Parents' Assessment of Risk in Sickle Cell Disease Treatment With Hydroxyurea. Journal of Pediatric Hematology/Oncology, 2005, 27, 644-650.	0.3	10
101	Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood, 2005, 106, 734-739.	0.6	312
102	Murine and Math Models for the Level of Stable Mixed Chimerism to Cure Î²-Thalassemia by Nonmyeloablative Bone Marrow Transplantation. Annals of the New York Academy of Sciences, 2005, 1054, 423-428.	1.8	12
103	Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry. Respiratory Care, 2005, 50, 624-7.	0.8	19
104	Enhanced Pulmonary and Systemic Response to Endotoxin in Transgenic Sickle Mice. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 687-695.	2.5	54
105	Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood, 2004, 103, 2822-2826.	0.6	130
106	Alpha Thalassemia is Associated With Decreased Risk of Abnormal Transcranial Doppler Ultrasonography in Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 622-628.	0.3	85
107	Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood, 2003, 102, 4582-4593.	0.6	56
108	A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complexâ€“mismatched bone marrow transplantation. Blood, 2002, 99, 1840-1849.	0.6	71

#	Article	IF	Citations
109	Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. Journal of Pediatrics, 2002, 140, 348-354.	0.9	215
110	Comparison of mechanisms of anemia in mice with sickle cell disease and Î²-thalassemia. Experimental Hematology, 2002, 30, 394-402.	0.2	68
111	Sickle erythrocyte adherence to endothelium at low shear: Role of shear stress in propagation of vaso-occlusion. American Journal of Hematology, 2002, 70, 216-227.	2.0	59
112	Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biology of Blood and Marrow Transplantation, 2001, 7, 665-673.	2.0	291
113	Silent Infarcts in Children With Sickle Cell Anemia and Abnormal Cerebral Artery Velocity. Archives of Neurology, 2001, 58, 2017.	4.9	112
114	Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology, 2001, 56, 1109-1111.	1.5	230
115	Social Information Processing and Magnetic Resonance Imaging in Children With Sickle Cell Disease. Journal of Pediatric Psychology, 2001, 26, 309-319.	1.1	31
116	Risk-resistance adaptation model for caregivers and their children with sickle cell syndromes. Annals of Behavioral Medicine, 2000, 22, 158-169.	1.7	46
117	Neurocognitive Functioning and Magnetic Resonance Imaging in Children With Sickle Cell Disease. Journal of Pediatric Psychology, 2000, 25, 503-513.	1.1	111
118	Transgenic HbS Mouse Neutrophils in Increased Susceptibility to Acute Lung Injury. Chest, 1999, 116, 92S.	0.4	10
119	RBC Adhesion to Cremaster Endothelum in Mice with Abnormal Hemoglobin is Increased by Topical Endotoxin. Annals of the New York Academy of Sciences, 1998, 850, 391-393.	1.8	3
120	Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129.	2.0	228
121	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11.	13.9	1,699
122	Prevention of Stroke by Transfusions in Children with Sickle Cell Anemia. New England Journal of Medicine, 1998, 339, 1477-1478.	13.9	12
123	Family Functioning and Social Support in the Adaptation of Caregivers of Children With Sickle Cell Syndromes. Journal of Pediatric Psychology, 1998, 23, 377-388.	1.1	45
124	Assessing the Appropriateness of Medical Care. New England Journal of Medicine, 1998, 339, 1478-1481.	13.9	2